Search

Your search keyword '"ReoPro (Medication) -- Evaluation"' showing total 19 results
Start Over Descriptor "ReoPro (Medication) -- Evaluation"
19 results on '"ReoPro (Medication) -- Evaluation"'

3. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions

Author

Kleiman, Neal S., Grazeiadei, Nikki, Maresh, Kelly, Taylor, Rebecca J., Frederick, Bart, Lance, Ellen T., Effron, Mark B., Jordan, Robert E., and Mascelli, Mary A.

Subjects
Blood platelets -- Aggregation, Stent (Surgery) -- Physiological aspects, Ticlopidine -- Evaluation, Health, ReoPro (Medication) -- Evaluation
Published
2000

4. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors

Author

Lincoff, A. Michael, Califf, Robert M., Moliterno, David J., Ellis, Stephen G., Ducas, John, Kramer, Jeffrey H., Kleiman, Neal S., Cohen, Eric A., Booth, Joan E., Sapp, Shelly K., Cabot, Catherine F., and Topol, Eric J.

Subjects
ReoPro (Medication) -- Evaluation, Heart attack -- Prevention, Stent (Surgery) -- Evaluation
Abstract

Giving patients with coronary artery disease a stent plus the drug abciximab appears to be the most effective treatment for preventing a heart attack. A stent is a small cylindrical device that is inserted into an artery to keep it open. Abciximab is a drug that prevents the formation of blood clots. Researchers randomly assigned 2,399 patients with coronary artery disease to receive a stent only, a stent and abciximab, or balloon angioplasty plus abciximab. The lowest rate of heart attack and death occurred in the group that received a stent and abciximab.

Published
1999

11. Tirofiban vs. Abciximab during PCI. (Abstract & Commentary)

Subjects
Tirofiban -- Evaluation, Abciximab -- Evaluation, Pharmaceutical industry -- Product information, Coronary heart disease -- Drug therapy, Ischemia -- Prevention, Health, Aggrastat (Medication) -- Evaluation, ReoPro (Medication) -- Evaluation
Abstract

THE DO TIROFIBAN AND REOPRO GIVE SIMILAR EFFICACY? (TAR-get) Trial, was the first (and thus far, the only) trial to directly compare 2 glycoprotein IIb/IIIa inhibitors in a 'head-to-head' fashion. [...]

Published
2002

12. Capsules; Studies Cite 2 Drugs for Heart Treatment

Author

Maugh, Thomas H., II

Subjects
Tirofiban -- Evaluation, Heart attack -- Drug therapy, Chest pain -- Drug therapy, General interest, News, opinion and commentary, ReoPro (Medication) -- Evaluation
Published
2001

13. A type of heart drug wins wide use owing to small firm's efforts

Author

Winslow, Ron

Subjects
COR Therapeutics Inc. -- Marketing, Johnson & Johnson -- Marketing, Eli Lilly and Co. -- Marketing, Pharmaceutical industry -- Marketing, Blood clotting disorders -- Drug therapy, Arterial occlusions -- Drug therapy, Business, Business, general, Integrilin (Medication) -- Evaluation, ReoPro (Medication) -- Evaluation
Published
2000

15. Routine use of abciximab in coronary stenting?

Author

Stables, R. H.

Subjects
ReoPro (Medication) -- Evaluation, Stent (Surgery) -- Health aspects, Transluminal angioplasty -- Methods, Blood platelets -- Aggregation, Arteries -- Stenosis
Published
1998

17. Eptifibatide has long-term benefit, cost-efficiency: ESPRIT trial changed coronary-stent practices

Subjects
Stent (Surgery) -- Methods, Health care industry, Pharmaceuticals and cosmetics industries, ReoPro (Medication) -- Evaluation, Integrilin (Medication) -- Evaluation
Abstract

Several months have passed since the release of the six-month results of the ESPRIT (Enhanced Suppression of the Platelet Receptor glycoprotein IIb/IIIa using Integrilin Therapy) trial. During this time, many [...]

Published
2001

18. Eli Lilly and Co. (Indianapolis, Indiana) said ReoPro (abciximab) improves the recovery of patients with ischemic stroke when administered up to six hours after stroke onset, according to data from AbESTT (Abciximab in Emergent Stroke Treatment Trial) presented at the 12th European Stroke Conference in Valencia, Spain. (Product Pipeline)

Subjects
Eli Lilly and Co. -- Product development, Pharmaceutical industry -- Product development, Stroke (Disease) -- Care and treatment, Abciximab -- Evaluation, Business, Health care industry, ReoPro (Medication) -- Evaluation
Abstract

* Eli Lilly and Co. (Indianapolis, Indiana) said ReoPro (abciximab) improves the recovery of patients with ischemic stroke when administered up to six hours after stroke onset, according to data [...]

Published
2003

19. ReoPro shows positive six-month results

Subjects
Centocor Inc. -- Product information -- 00301465, Pharmaceutical industry -- Product information, Biotechnology industry, Business, ReoPro (Medication) -- Evaluation
Published
1996

Catalog

Books, media, physical & digital resources
See catalog results